## KVUE: Kenvue Inc. - XLP: Consumer Defensive

### Executive Summary

VALUE thesis: PEG 0.86 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($16.14)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Guggenheim Capital LLC Raises Stock Position in Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251207T110114 | Somewhat-Bullish | Relevance: 99%
-  Guggenheim Capital LLC significantly increased its stake in Kenvue Inc. (NYSE:KVUE) by 33.3% in the second quarter, now owning 255,061 shares valued at $5.338 million. This move is part of broader institutional investor activity in Kenvue, with several firms acquiring or boosting their positions. Analysts have issued varied ratings, with a consensus "Hold" and an average price target of $20.23, while Kenvue recently reported quarterly earnings and declared a dividend.

**2. Paxton Secures Major Win Against Johnson & Johnson and Kenvue**
- Source: Texas Border Business | 20251208T191740 | Neutral | Relevance: 99%
-  Attorney General Ken Paxton secured a legal victory against Johnson & Johnson and Kenvue, obtaining a Temporary Restraining Order for their operations in Texas without required registrations. The companies failed to comply with the Texas Business Organizations Code, which mandates foreign entities to register before conducting business in the state. Paxton emphasizes his commitment to holding powerful corporations accountable and protecting Texans' well-being over corporate greed.

**3. Brown Advisory Inc. Cuts Position in Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251207T090143 | Neutral | Relevance: 99%
-  Brown Advisory Inc. reduced its stake in Kenvue Inc. by 8.2% in the second quarter, selling 114,055 shares while still owning 1,283,006 shares valued at $26.85 million. Despite this, other major institutional investors like Amundi and Invesco increased their positions, with hedge funds and institutions collectively holding approximately 97.64% of Kenvue's stock. Kenvue (NYSE:KVUE) currently trades around $16.92, offers a 4.9% dividend yield with a 110.7% payout ratio, and has a consensus "Hold" rating from analysts with an average price target of $20.23.

**4. Kenvue Inc. $KVUE Position Raised by Ossiam**
- Source: MarketBeat | 20251208T115129 | Neutral | Relevance: 99%
-  Ossiam significantly increased its stake in Kenvue Inc. (NYSE:KVUE) by 679.3% in the second quarter, bringing its total holdings to 1,332,897 shares valued at approximately $27.9 million. This move is part of broader institutional investment trends, with various other firms also adjusting their positions in Kenvue, which currently holds a consensus "Hold" rating from analysts with an average target price of $20.23. The company recently reported Q3 earnings per share of $0.28, beating estimates, and announced a quarterly dividend reflecting a 4.9% yield.

**5. The Motley Fool: Kimberly-Clark is growing**
- Source: Dallas News | 20251207T110314 | Bullish | Relevance: 98%
-  Kimberly-Clark is acquiring Kenvue for approximately $48.7 billion, creating a health and wellness giant projected to generate $32 billion in revenue and boasting ten brands with over $1 billion in annual sales each. The deal is expected to yield a net benefit of $2.1 billion within four years and strengthen the combined company's financial position, despite initial debt; however, potential legal issues remain a risk. The article also provides general investment advice, including an explanation of "earnings season" and Philip A. Fisher's 15 points for evaluating common stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Barclays | $18 | $17 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Barclays | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.0%)
- Blackrock Inc.: 7.6% (-1.9%)
- Price (T.Rowe) Assoc: 6.0% (-31.5%)
- State Street Corpora: 6.0% (-0.2%)
- FMR, LLC: 4.7% (-9.3%)

### Key Risks

1. Long-term trend broken: trading 16.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Forward P/E 15.4x stretched relative to 7% growth. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $32.7B |
| Beta | 0.56 |
| 52W Range | $14.02 - $25.17 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 15.4 |
| Current P/E | 16.5 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 4.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Below SMA200 (0.83x), long-term trend not supportive. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.57% (CS: 55) | Neutral |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | -0.00 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 0.832x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $17.02
- **Stop Loss:** $16.14 (5.2% risk)
- **Target:** $18.78 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 568
- **Position Value:** $9,667.36
- **Portfolio %:** 9.67%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.26 | $0.28 | +5.7% |
| 2025Q2 | $0.28 | $0.29 | +2.2% |
| 2025Q1 | $0.23 | $0.24 | +5.4% |
| 2024Q4 | $0.26 | $0.26 | +1.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*